Scientists test Patient's own cells to calm painful skin disease
NCT ID NCT06361836
Summary
This early-stage study is testing a new personalized cell therapy called SBT777101 in adults with moderate-to-severe hidradenitis suppurativa (HS), a painful chronic skin condition. Researchers will give single doses to 24 participants to check if the treatment is safe and how the body handles it. The therapy uses the patient's own immune cells, modified to target inflamed tissue and potentially reduce inflammation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Duke University
Durham, North Carolina, 27708, United States
-
SLUCare Academic Pavillion
St Louis, Missouri, 63110, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.